New drug cocktail shows promise for hard-to-treat lung cancer
NCT ID NCT05751187
First seen Mar 18, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study tests whether combining pembrolizumab (an immunotherapy), bevacizumab (a drug that blocks blood vessel growth), and standard chemotherapy can help people with advanced non-squamous non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. About 54 participants will receive this combination as their first treatment. The main goal is to see how many patients' tumors shrink or disappear, and researchers will also track how long it takes for the cancer to progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.